At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 28 enrolled
Drug / intervention
Sintilimabdrug
Likely dose
Sintilimab 200mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Efficacy and Safety Evaluation of IBI308 in Patients With Relapsed/Refractory Extranodal NK/T Cell Lymphoma, Nasal Type: a Multicenter, Single Arm, Phase 2 Study (ORIENT-4)
In Brief
A Phase 2 clinical trial evaluating Sintilimab for Effect of Drugs. Completed, enrolled 28 participants across 1 site.
Detailed Summary
This is phase II study. Efficacy and safety evaluation of IBI308 in patients with relapsed/refractory extranodal NK/T cell lymphoma, nasal type: a multicenter, single arm.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEffect of Drugs
CountriesChina
Collaborators--
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedJul 2017
Enrollment StartAug 2017
Primary CompletionFeb 2020
TodayJul 2026
First PostedJul 25, 2017
Enrollment StartAug 23, 2017
Primary CompletionFeb 28, 2020
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 8.9 years ago
Interventions
Sintilimabdrug
Sintilimab (IBI308) 200mg IV Q3W